2027 ARCS

ANNUAL CONFERENCE

16-18 June 2027



CALL FOR ABSTRACTS/PROPOSALS

Conference Submission Guidelines

2027 ARCS Annual Conference Theme

From Possibility to Impact

From discovery and development through regulation, evidence, safety, launch, access and beyond.

The 2027 ARCS Conference Abstract Submission Portal can be accessed via the LifeSciences Australia website under Events>Annual conference or directly here.

2027 ARCS Annual Conference Call for Abstracts

LifeSciences Australia wishes to invite all interested parties from industry, research institutions, healthcare consumers, government and academia involved in development through to commercialisation of therapeutics to make program submissions for the 2027 ARCS Annual Conference (16-18 June 2027) to be held at the International Convention Centre (ICC), Darling Harbour, Sydney.

We have highlighted priority topics within each educational theme to provide direction on content you may wish to consider. You may submit abstracts addressing priority topics and/or topics relevant to the overall stream. Both priority topics and theme specific topics will be reviewed and considered by the LifeSciences Australia **Annual Conference Program Committee (ACPC)**. More information located in Appendix A.

- Clinical Governance, Sponsor, CRO
- Leadership, wellness & resilience
- GxP/Manufacturing
- Medical Operations/Medical Affairs/MSL/Med Info
- Regulatory Devices
- Reimbursement/Market Access
- BioBeacon/Drug- /Device- Discovery
- Clinical Research Sites
- Government updates
- Commercial
- Regulatory Non-prescription medicine (OTC and Complementary Medicines)
- Pharmacovigilance
- Regulatory Prescription medicines
- Diversity, inclusiveness and consumer engagement
- General Interest
- Artificial Intelligence/Technology

Members and non-members of LifeSciences Australia are invited to make submissions in accordance with these Submission Guidelines. In selecting sessions, consideration will be given to the quality and relevance of the proposal, its appeal to a cross-functional audience, and alignment with the areas identified in these Guidelines. **Preference will be given to proposals involving LifeSciences Australia members, and submissions which include a patient or consumer perspective are particularly encouraged.** Not yet a member? Join LifeSciences Australia and be part of the conversation.

SUBMISSION TIPS & STEPS

These will help ensure that you have all the required information available before submitting your proposal. All submissions must be submitted online by the designated deadline. See page 23 - 25 for more details.

MAKE A SUBMISSION TODAY

Please ensure your submission is completed in compliance with the Submission Guidelines no later than midnight **01 DECEMBER 2026.**

REWARD AND RECOGNITION

LifeSciences Australia offers complimentary registration for speakers accepted into the program on the day they are presenting. Speakers also receive heavily discounted rates for any additional days they attend as non-speakers. Further details will be provided in the Speaker Guidelines in Q1 2027.

CONTACT US

If you have any questions, **please email us at** info@lifesciences.au

Submission Guidelines

1. Submission types and formats

We encourage submissions which are thought provoking and include the sharing of actual case studies to promote information exchange and knowledge sharing.

Abstracts may be submitted for the following types of sessions:

- **1 hour speaking slot** (1 speaker)
- **1 hour speaking slot** (2 speakers)
- **30 min speaking slot** (1 speaker)
- **1 hour panel** (1 chair and up to 3 panellists max)

Session Type	Duration	Format	Speakers
Speaking Slot	1 hour	Information/ Workshop	1 or 2
Speaking Slot	30 min	Information	1
Panel	1 hour	Forum	1 chair + up to 3 panellists
Workshop	1 hour	Hands-on	1 or 2

There are various formats for sessions:

Information

An information session is delivered lecture-style from the podium. LifeSciences Australia will provide a chair to introduce the speaker and facilitate question and answers from the audience. PowerPoint presentations are required.
1 hour speaking slot (1 speaker) or
1 hour speaking slot (2 speakers) or
30min speaking slot (1 speaker only)

Workshop

A workshop is designed for hands-on learning with a focus on application. The abstract submitter is considered as one speaker and ensures the workshop provides learning in the form of activities or demonstrations, including handouts (accessed via the conference app).
1 hour speaking slot (1 speaker) or
1 hour speaking slot (2 speakers) or

Forum

A forum is designed for panel interaction and attendee engagement. The submitter acts as forum chair, recruiting a maximum of 3 panel members and ensuring good representation/diversity in their selection. Any PowerPoint slides must be consolidated by the chair into one deck

1 hour panel (1 chair and up to 3 panellists max)

Submission Guidelines

2. General instructions for submitters (or authors)

- Submissions should reflect contemporary, new and evolving areas of work practices, policy and/or approaches.
- Submissions for sessions should include diverse perspectives from a range of organisations.
- Submissions which include a patient or consumer perspective are encouraged.
- Each session must include all the required information contained within the submission planning form including full details of the speakers (full name, position, affiliation, email).
  Incomplete abstracts may not be assessed during the initial consideration (round one offers) of the ACPC.
- ACPC will include abstracts in the program based on educational need, relevance to the LifeSciences Australia membership, content and general fit within the program.
- LifeSciences Australia reserves the right to accept, reject or change submissions (including speaker suggestions and type/format) at its sole discretion to ensure a complete and balanced program.
- All submissions must adhere to the LifeSciences Australia policy prohibiting explicit promotion of products or services by session speakers or chairs.
- A good session with multiple speakers includes discussion with differing and competing perspectives. Consider diversity in the speakers and organisation.

3. Sessions involving a TGA speaker(s)

LifeSciences Australia has a formal process for requesting TGA speakers for the conference. The ACPC kindly requests that individuals do not contact the TGA directly in regard to speaking at the conference.

Instead, please include the details of the speaker where known and the specific topic(s) you would like covered (e.g., "Someone from the medical device authorisation branch (such as Joe Blogs) able to speak on the latest update to..."). Feedback from past conferences is, attendees value it when a substantial portion of the session involving TGA is dedicated to Q&A. The ACPC is calling for submissions from individuals able to provide an industry perspective (e.g., contribute as a speaker).

Any request for a TGA speaker(s) must be accompanied by a full abstract and the full names of any non-TGA speakers (name, position, organisation). All requests for TGA speakers are submitted to TGA for consideration with a final decision anticipated by the end of March 2027. Please have a contingency in place if TGA declines participation in your session.

Please note that TGA branch updates are already covered and separate abstracts are not required from the sector for these.

Submission Guidelines

4. Engaging your audience

The ACPC encourages submissions which balance content delivery and audience involvement. The conference will have polling capability which allows you to "ask the audience", check understanding on presented case studies, prioritise topics for a panel or introduce a game to keep people engaged. If you like these ideas and/or have other interactive ideas for your proposed session(s) or presentation(s) please add these as part of your submission in your abstract. The LifeSciences Australia team is here to help you through this process!



5. Making a submission

1. Submissions must be made in accordance with these Submission Guidelines.
2. To help you plan for your online submission, we recommend you review the submission tips and steps at the end of this document. This will help ensure that you have all the required information available before making your online submission.
3. Review the process for including a TGA speaker in your session (if applicable).
4. For sessions involving multiple speakers, please work with those speakers to confirm their interest, collect their contact details and submit one abstract for that session (ie. Don't submit separate abstracts for the same session for each speaker).
5. Each session and speaking slot submission must include all the required information described in the portal including full details of the speakers (full name, affiliation, role, email). Incomplete submissions may not be assessed during the initial consideration (round one offers) of the ACPC.
6. Make your submissions via the online submission portal by the designated deadline.

Please note that the official submission needs to be completed online prior to 1-Dec-2026 deadline and can be accessed via the LifeSciences Australia website under Events>Annual conference or directly here.

Submission Guidelines

6. The role of the chair for panels and ACPC for other sessions

The chairperson/Annual Conference Program Committee (ACPC) is critically important to the success of the session. The role of the chair/ACPC is to manage the development and delivery of the session by:

- Developing the topic and session outline
- Identifying and making contact with the speakers. Sharing the learning objectives with potential speakers as early as possible to assist them to develop their material
- Assisting with uploading the proposal to the online portal
- Adding confirmed speakers to the session via the online portal
- Keeping the proposal updated via the online portal
- Ensuring the speakers are familiar with the policy "Explicit promotion of products or services from the podium" (see section 8)
- Working with all speakers as a team to develop the session and deliver on time
- Reviewing presentations for length, relevance and to avoid duplication between speakers
- Managing the session "on the day"

7. Speaking at the conference

The 2027 ARCS Annual Conference is an in-person event with speakers and panellists presenting in person. Provision for remote participation (via pre-recorded video) has been made for international speakers only.

8. Explicit promotion of products or services from the podium

LifeSciences Australia is a professional association which focuses on career long professional development for its members in the medtech and pharmaceutical sector. LifeSciences Australia provides education, competency building and information sharing within communities of practice, and targeted advocacy and collaboration with a range of stakeholders. Our membership is made up of individuals working in regulatory affairs, clinical research, health economics, medical information and other disciplines who work in the development and quality use of therapeutic goods. LifeSciences Australia members are based in industry, academia, medical research institutes, government, hospitals and patient groups.

LifeSciences Australia appreciates the contribution made by all speakers at LifeSciences Australia events. In order to maintain the integrity of the educational content, all speakers at LifeSciences Australia events, whether members or not, are expected to limit their presentation to the technical, scientific or procedural topic under discussion.

Speakers from organisations and institutions which provide services or products must not overtly endorse or recommend a product or service during the course of the presentation.

The content of slides, handouts and other presentation aids should not promote a commercial product or service.

Submission Guidelines

9. Sponsored sessions

LifeSciences Australia does offer exhibitors and sponsors the opportunity to promote products and services as sponsored sessions. These sessions are separated from the educational sessions (and are identified accordingly). These sessions are not reviewed by the ACPC. Please refer to the 2027 ARCS Annual Conference Sponsorship and exhibition prospectus or contact LifeSciences Australia at info@lifesciences.au if you are interested in learning more able our sponsored session offering at the conference.

10. Planning dates for the diary

Call for abstracts close	01 Dec 2026
Notification of program committee outcome	Q1 2027
Speaker requirements due - including biography, photo, permissions	16 Feb 2027
Presentations & polls	11 May 2027



LifeSciences Australia reserves the right at its sole discretion to update the information contained within these guidelines.

Conference Themes

1. Clinical Research
   a) Governance
   b) Site
   c) Sponsor
   d) CRO
2. Artificial Intelligence/Technology
3. Leadership, wellness & resilience
4. Medical Devices Regulation
5. Reimbursement/Market Access/Health Economics
6. Medical Operations/Medical Affairs/MSL
7. Non-prescription medicine (OTC and Complementary Medicines) Regulation
8. Prescription medicines Regulation
9. Pharmacovigilance
10. Diversity, inclusiveness and consumer engagement
11. GxP/Manufacturing
12. General Interest
13. BioBeacon/Drug or Device Discovery
14. Commercial
15. Government Updates/State/Federal
16. International Government

Subject to change based on abstracts received

APPENDIX A. Themes and priority areas

The following are only provided as a guide and general areas/themes of interest (they are not the streams); however, additional submitted topics will be considered by the ACPC (topics included in each area are guides only and are not exhaustive).

Clinical

Topics of interest are welcome from industry in both interventional and non – interventional research and topics of interest include, but not limited to:

- Innovation in protocol and trial design to enable flexibility in times of continuous change
- Key international and local clinical research updates
- Non-clinical and early phase clinical trials
- Indigenous health
- Site management – feasibility, selection, budgets and contracts
- Regulation and guideline updates and their impact on clinical research
- Clinical collaborations
- Monitoring trends
- Quality compliance and risk management - audit (practices and outcomes)
- HREC/Governance – innovation, current trends, state/ jurisdictional differences, compliance and oversight of clinical trials
- Patient engagement
- Registries
- Resourcing and skilling of the clinical research workforce

APPENDIX A. Themes and priority areas

Artificial Intelligence/Technology

Topics of interest are welcome from industry in both interventional and non-interventional research and topics of interest include, but not limited to:

- Regulation and guideline updates and their impact on data management
- Clinical trial innovation (COA, ePROs, apps,VR, AI, AR, mobile technology, wearables, telemedicine, EMR, portals, software, hardware etc.)
- Clinical research involving IVDs, digital medical devices & diagnostics
- Social media and clinical trials
- Digital medicine and digital therapeutics
- Use of Artificial Intelligence
- Emerging technology and clinical trials including, EDC, eConsent, eSignature, CTMS, eTMFs, EMR, AI, block chain including validation and audit of these systems
- Detection and prevention of fraud and misconduct in clinical trials
- Analytics and big data – recruitment, clinical evidence, connectivity
- The impact of change in trial conduct (RBM, decentralised trials) on data management
- Preparing the workforce for technology integration

APPENDIX A. Themes and priority areas

Leadership, wellbeing & resilience

This interest area is composed of sessions addressing topics and issues relating to self-leadership, wellbeing & resilience. Topics of interest include, but not limited to:

- Managing and leading
- Creating work-life balance
- Self-regulation & awareness
- The ability to inspire and convince others
- Strategic thinking skills
- The ability to turn information into action
- Active listening
- Influence
- Flexibility
- Project planning
- Building trust
- Time management
- Communication skills
- Persuasion skills
- Increasing resilience & mindfulness
- Cultivating positive emotions
- Mental agility and flexibility; and
- Decision making

APPENDIX A. Themes and priority areas

GxP/Manufacturing

Topics should relate to manufacturing and quality management best practices from a manufacturer (local or overseas) and an Australian sponsor perspectiveTopics of interest include, but not limited to:

- GMP inspection trends inspection reliance
- Remote GMP inspections
- GMP clearances (including managing the backlog)
- Update on PIC/S guide to GMP for medicinal products version 14
- GMP compliance for listed medicines
- GMP implementation ofTGOs 92 and 101
- GxP Principles
- GMP requirements in emerging areas such custom medical devices, gene therapy, genomic editing, cell therapy and tissue engineering & regenerative medicine
- GMP licence applications
- Manufacturing investigational medicinal products
- Management of GMP compliance signals
- Implications of complex global supply chains
- GxP contracts, procedures, guidance

APPENDIX A. Themes and priority areas

Medical Operations/Medical Affairs/MSLs

This interest area is composed of sessions addressing topics and issues relating to those working in a medical operations/affairs role, but not limited to:

- Up skilling in therapeutic area knowledge
- Scientific meeting planning
- Managing the KOL relationship
- Creating synergy between marketing and medical affairs
- Metrics and the medical affairs value proposition
- Building scientific awareness
- Patient engagement
- Legal and regulatory developments impacting medical information (including privacy & information security, code of conduct)
- Healthcare professional and patient engagement (including HCP & consumer engagement, scientific exchange, awareness of medical information services)
- External partnerships (including public health initiatives, collaboration with professional societies)
- Medicines code of conduct
- Initiating and maintaining relationships with healthcare customers
- Compliance with legal and regulatory guidelines
- Gathering and providing competitive intelligence
- Aspects of Medical Information
- Aspects of contract development
- Patient Support programs
- Technology in medical information (including search engine optimisation, artificial intelligence and natural language processing, digital channels
- Medical information professional development (including customer facing skills, contact centre management, medical writing, multifunctional collaboration
- Outsourcing, third party management and vendor oversight

APPENDIX A. Themes and priority areas

Medical device regulation

This interest area is composed of sessions addressing laws, regulations, guidelines and classification rules that govern medical device approval and maintenance. Sessions may focus on implementation, approaches, insights, updates including (but not limited to):

- Reforms to IVDs (companion diagnostics, self-tests)
- Local alignment with EU MDR
- New clinical evidence guidance for medical devices
- Impact of the repeal of conformity assessments
- Post market monitoring and surveillance
- Medical device patient information leaflets and implant cards
- Unique Device Identification (UDI)
- Software as a Medical Device (SaMD)
- Custom made medical devices & Medical Device Production Systems (MDPS)
- Australian conformity assessment bodies (AU CABS)
- Comparable overseas regulators
- MDSAP experiences
- Regulatory changes impacting Australian regulatory requirements (in particular, comparable overseas regulators, ASEAN, Japan, Korea and China)
- Conformity assessment in emerging areas (such as SaMD & PMD & MDPS)
- Challenges/approaches to regulatory changes through the supply chain

APPENDIX A. Themes and priority areas



Reimbursement/Market Access/Health Economics – Devices

This interest area focuses on current issues related to the generation, analysis, and utilisation of evidence to assess the impact of medical technology products on health outcomes.Topics of interest include, but are not limited to:

- Impact of the new MASC guidelines
- Update on the MASC cost recovery process
- Prostheses list reforms
- The patient voice in health technology assessment
- Funding pathways for digital healthcare (including use of digital health formularies)
- Value-based healthcare
- Real world evidence (including registers)
- Health technology assessment in emerging areas such custom medical devices, machine leaning assisted software and robotic surgery

APPENDIX A. Themes and priority areas

Reimbursement/Market Access/Health Economics – Medicines

This theme is composed of sessions addressing the generation, analysis, and utilisation of evidence to assess the impact of medicines on health outcomes. Sessions may focus on implementation, approaches, insights, updates including (but not limited to):

Health technology analysis (HTA) review including:
- How uncertainty is shared and managed, speed to access, ICER thresholds and discount rates
- HTA assessment processes (including horizon scanning, conditional listing arrangements, repurposing of medicines, and lowest cost comparator)

- How the PBAC assesses value for money? What is the value of life and quality of life?
- The patient voice in HTA (and the use of lived experience)
- Post-PBAC processes including
  - Special pricing arrangements, risk sharing arrangements, price certainty, post market review framework, new therapeutic groups and rapid post- market reviews)
- Funding pathways for digital healthcare (including use of digital health formularies)
- Funding pathways for Advanced Therapy Medicinal Products (ATMPs) including gene therapy, genomic editing, cell therapy and tissue engineering & regenerative medicine
- The access gap generated by the new TGA regulatory accelerated approval pathways
- The broader societal effects of medicines and technology on society
- Resourcing and skilling of the HTA workforce

APPENDIX A. Themes and priority areas

Non-prescription medicines regulation (OTC and complementary medicines)

This stream is composed of sessions addressing laws, regulations, and guidance's that govern non-prescription medicine approval, and maintenance. Sessions may focus on challenges, issues, approaches, strategies and updates including (but not limited to):

- Cannabidiol based products (Schedule 3) pathways
- New assessed listed medicines (Aust L(A) pathway)
- Permitted indications for listed medicines
- TGA assessed claim
- Evidence guidance restructure and update
- Enhance supply chain resilience (& Australian manufacturing)
- Down scheduling/SUSMP application
- Digital health and the non-prescription medicine sector
- Review of the therapeutic goods advertising code
- Reforms for applications for new ingredients for listed medicines
- Mandatory requirements for new ingredients applications
- Post-market compliance reviews

APPENDIX A. Themes and priority areas

Pharmacovigilance

This theme is composed of sessions addressing laws, regulations, and guidance's that govern the detection, assessment, understanding and prevention of adverse effects of medicine and vaccines. Sessions may focus on challenges, issues, approaches, strategies and updates including (but not limited to):

- New regulatory requirements and expectations regarding drug safety
- Pharmacovigilance audits/inspections
- Managing remote audits and inspections
- Significant safety issues (including application of the new guidelines)
- Benefit-risk assessment and management (including additional risk minimisation measures)
- Safety considerations with combination products
- Safety considerations with Advanced Therapy Medicinal Products (ATMPs) including gene therapy, genomic editing, cell therapy and tissue engineering & regenerative medicine
- Aspects of Periodic reports and Risk Management Plans
- Application of artificial intelligence to pharmacovigilance
- Good pharmacovigilance practices
- Product safety and new data sources (including social media)
- Signal detection and management across the product lifecycle.
- Pharmacovigilance in clinical trials/special access/ Investigator initiated trials
- Pharmacovigilance and advanced therapeutic techniques
- The future of pharmacovigilance (changing role of the pharmacovigilance professional)
- New drug applications from a pharmacovigilance perspective
- Risk Minimisation Materials

APPENDIX A. Themes and priority areas

Prescription medicine regulation

This theme is composed of sessions addressing laws, regulations, and guidelines that govern prescription medicine approval, and maintenance. Sessions may focus on challenges, issues, approaches, strategies and updates including (but not limited to):

- Transitioning from provisional approvals to full applications
- Labelling orders TG091/92 process
- Practical insights in registering medicines with Health Canada, Health Sciences Authority, Singapore, Swissmedic and MHPRA
- Impact of BREXIT on the comparator overseas pathways
- Application of the reliance pathways (including priority and provisional pathways, COR-A and COR-B, ACCESS work-sharing & Project Orbit)
- TGA/PBAC submission interface (joint clinical evaluation)
- Use of Real-World Evidence (RWE) & PROs in regulatory applications
- Rare diseases and repurposing of medicines & orphan drug pathways
- TGA digital transformation project
- CMC changes and post-approval protocol (ICH Q12)
- New Zealand regulatory update (including legislative reforms, digital transformation, work sharing plans, resourcing)
- The patient voice in regulatory decision making
- Global supply chain management
- Medicine's shortages information initiative & mandatory reporting
- Generics & biosimilars development
- Using AI in Regulatory processes

APPENDIX A. Themes and priority areas

2.

Small and Medium Enterprises (SME) support/BioBeacon/Drug/Device Discovery

Proposals on topics of interest for start-ups (founders), SMEs (leaders with responsibilities for appointing clinical trial partners and or strategic development), commercialisation executives & clinicians and researchers.The purpose of these sessions are informational, roundtables, storytelling and awareness building for new entries into the SME space.Topics of interest include but not limited to:

- Investor communication
- Commercial judgment
- Opportunity and unmet need identification
- Intellectual property strategy and management
- Who is the customer & positioning the technology or product.
- The disconnect between early-stage development and commercialisation
- Business and commercialisation development plan
- Market analysis (local and global)
- Stakeholder management
- Regulatory requirements (local and global)
- Funding models (who will pay)
- Strategic partnerships
- Translational understanding
- Project planning and management
- Budget development and management

APPENDIX A. Themes and priority areas

Diversity, inclusiveness and consumer engagement

This theme is composed of sessions which engage in discussions, share innovative strategies and inspire positive change within organisations.

- Topics of interest include but not limited to:

- Consumer journey and experiences
- Engaging Consumers across therapeutic development (trial design, risk, quality, safety, communications)
- Improving access to clinical trials
- Cultural competence and diversity initiatives
- Gender diversity
- Multigenerational workforce

APPENDIX A. Themes and priority areas

Commercial

This theme focused primarily on the future of commercial strategy, digital innovation and technology, within the pharmaceutical industry.

- Topics of interest include but not limited to:

- HCP & Customer Experience
- Scaling Omnichannel
- Evolution of Field Roles
- Pharma Product Launches
- Medical-Commercial Alignment:
- HCP Education & Health Literacy
- Multigenerational workforce
- Patient Centricity
- Health Digital Enablement
- Tailored Market Strategies
- Current local industry landscape, regulatory friction, and investment climates

Abstract Submission tips

Getting ready

We recommend preparing your presentation title (<25 words), abstract/s (<300 words) and your biography (<200 words) in a separate document (e.g., Microsoft Word) before entering it into the portal to prevent data loss due to technical issues or timeouts.

Your abstract is a summary of your proposed presentation. Please ensure it meets the following criteria:

- ***Title:*** Your presentation title should not be longer than 25 words. A short, succinct title that describes your topic clearly is ideal.
- ***Clarity & Detail:*** Provide sufficient information for reviewers and regulatory bodies to understand your topic.
- ***Length:*** Abstracts should be more than just 1–2 sentences but no more than 300 words. Incomplete or overly brief submissions will not be reviewed.
- ***References:*** While not mandatory, you may include references or a bibliography if relevant.
- ***Content:*** Focus on the purpose, approach or methodology, key findings or insights (where applicable), and the implications or key takeaways from your proposed presentation.

Abstract Authors

It is assumed that you are submitting an abstract as a presenting author. Additional authors are assumed to be speakers/panellists. Please ensure you have the following details of your additional speakers/panellists ready to include in the portal.

First Name
Last Name
Organisation
Position
Primary email

Only one submission is required for a particular abstract. Each speaker is not required to submit separately. Preference will be given to LifeSciences Australia members. Not a member? Become one now!

Need Help?

If you encounter any issues or have questions during the submission process, please contact: LifeSciences Australia Support Team – info@lifesciences.au

Abstract Submission Portal Steps

To begin your submission, please follow the steps outlined below.

Step 1: Abstract Submission Portal Sign In

Start by visiting the Abstract Submission Portal Sign In Page: https://arcs.eventsair.com/2027-arcs-annual-conference/abstractsubmit

- If you have not yet created an account for the 2027 ARCS Conference Submission, click Create New Account.
- Complete your email address and enter a password
- Click Create New Account.

Step 2: Home Page Overview

Welcome to the Abstract Submission Portal.

- To begin the submission process, go to the Contact Information tab.

Step 3: Contact Information

- This section displays your primary contact details.
- To update your information, click the Edit Contact Details button at the bottom of the screen.
- If no details are present, click Create Contact and complete your information.
- After creating your contact, additional tabs will appear that will enable you to submit your abstract.

Step 4: Abstract Submission

This page guides you through the abstract submission process.

- Use the tabs on the left-hand side to complete each step.
- You can click Save As Draft at any time to save your progress and return later.
- The Review section will show which sections are incomplete.
- Once all required sections are completed, go to the Submit section to finalise your submission.

Submission Sections Include:

1. Title and Presentation Type

- Enter your abstract title (within the specified word limit).
- Select your presentation type from the dropdown:
  - 1 hour speaking slot (1 speaker)
  - 1 hour speaking slot (2 speakers)
  - 30 min speaking slot (1 speaker)
  - 1 hour panel (1 chair and up to 3 panelists)

2. Themes and Keywords

- Choose relevant themes and keywords to help categorise your abstract.

3. Authors and Affiliations

- List all contributing authors and their affiliations.

4. Abstract

- Paste your abstract text into the provided field.

5. Review

- Check for completeness and accuracy.

6. Submit

- Finalise and submit your abstract.

ARCS Abstract Submission Portal Steps

Edit Abstracts Tab

Your uploaded abstracts are listed below along with their status.
A red triangle means you can still edit your abstract if you wish. Once the red triangle is removed, you will no longer be able to update your abstract. To edit your abstract, click on the Edit button next to the relevant submission. If you are no longer able to edit your abstract, please contact info@lifesciences.au

Review Process

All abstracts will be reviewed by the ARCS Conference Program Committee.
Submissions may also be assessed by regulatory bodies, so accuracy and completeness are essential.
Abstracts will be reviewed and assessed against the following criteria

- Educational needs
- Relevance
- Content

Need Help?

If you encounter any issues or have questions during the submission process, please contact: LifeSciences Australia Support Team – info@lifesciences.au

LifeSciences Australia reserves the right at its sole discretion to update the information contained within these guidelines.

Version 1 (October 2026)